Impact of Acute Exercise Intensity and Pattern on Cytokine Function

Inflammation Clinical Trial

— AEX  

Official title:

Impact of Acute Exercise Intensity and Pattern on Cytokine Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05574413
• Other study ID #: AEX2022
• Status: Completed
• Phase: N/A
• Start date: September 15, 2022
• Est. completion date: September 1, 2023

Study information

• Verified date: December 2023
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The immune system helps prevent illness, fights off infections, and repairs damaged tissues following an injury. However, when immune cells remain active for prolonged periods of time - a state known as "chronic inflammation" - they can contribute to the development and progression of chronic diseases like heart disease and diabetes. Exercise can reduce the risk of developing many of these diseases and at least part of the health benefits of exercise are due to the ability of exercise to reduce "chronic inflammation". The inflammation-lowering effects of exercise are typically captured by measuring hormone-like molecules released from immune cells called "cytokines" in the blood. In addition to changes in circulating cytokine levels, exercise may also alter how immune cells respond to these cytokines. How exercise intensity (i.e., how hard you are working during exercise) and pattern (i.e., exercising as a long continuous bout or in short intervals) impact the ability of immune cells to respond to cytokines is not well understood. A better understanding of how exercise intensity and pattern of exercise for reducing chronic inflammation may help determine the best types of exercises for improving health and preventing chronic diseases.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: September 1, 2023
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• 18-35 years of age

• Body mass index between 18.5-30 kg/m^2

• Free of cardiometabolic and autoimmune/inflammatory disease

Exclusion Criteria:

• Competitive endurance athlete

• Cigarette smoker

• Currently taking immunomodulatory/anti-inflammatory medications

• Currently pregnant

Related Conditions & MeSH terms

• Inflammation

Intervention

Other:
• Moderate intensity continuous exercise
Participants will perform an acute bout of continuous cycling at 70% of the power output at lactate threshold until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
• High intensity continuous exercise
Participants will perform an acute bout of continuous cycling at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
• High intensity interval exercise
Participants will perform an acute bout of interval cycling at at 10% of the difference between lactate threshold and VO2peak until an energy expenditure of 350 kcal is achieved. Blood samples will be obtained immediately before and immediately, 30, and 90 minutes after exercise.
• Resting (no exercise) control
Participants will remain in a rested state (i.e., no exercise) for the entire session. Blood samples will be obtained at the same time-points as the exercise sessions.

Locations

Country	Name	City	State
Canada	UBC Okanagan	Kelowna	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IL-10 mediated STAT3 phosphorylation	Ex vivo leukocyte STAT3 phosphorylation in response to IL-10 treatment	Change from pre-exercise to immediately and 90-min post-exercise
Secondary	IL-10 mediated TNF-alpha inhibition	Ex vivo inhibition of TNF-alpha production in response to IL-10 treatment	Change from pre-exercise to immediately and 90-min post-exercise
Secondary	IL-6 mediated STAT3 phosphorylation	Ex vivo leukocyte STAT3 phosphorylation in response to IL-6 treatment	Change from pre-exercise to immediately and 90-min post-exercise
Secondary	IL-6 mediated TNF-alpha inhibition	Ex vivo inhibition of TNF-alpha production in response to IL-6 treatment	Change from pre-exercise to immediately and 90-min post-exercise
Secondary	Plasma IL-10	Concentration of IL-10 in plasma samples	Change from pre-exercise to immediately, 30-, and 90-min post-exercise
Secondary	Plasma IL-6	Concentration of IL-6 in plasma samples	Change from pre-exercise to immediately, 30-, and 90-min post-exercise
Secondary	Plasma TNF-alpha	Concentration of TNF-alpha in plasma samples	Change from pre-exercise to immediately, 30-, and 90-min post-exercise
Secondary	Hematology panel	Complete blood count	Change from pre-exercise to immediately, 30-, and 90-min post-exercise
Secondary	Extracellular vesicles	Concentration of extracellular vesicles in plasma	Change from pre-exercise to immediately, 30-, and 90-min post-exercise